Abstract 353P
Background
To date, there is limited information on Indian oncologists' views and experiences of geriatric oncology. This study aimed to explore the views of Indian oncologists regarding the perception of, and barriers to the incorporation of geriatric screening tools, GA and collaboration with geriatricians in routine clinical practice.
Methods
This was an anonymized cross-sectional survey. The online survey, based on a literature review and expert opinion, comprised 12 questions covering: (i) respondent characteristics, clinical practice environment and patient population; (ii) challenges and treatment decision-making factors in the management of older patients with cancer; and (iii) benefits of and barriers to the implementation of GA or geriatrician review in cancer care for older patients. Qualitative variables were reported as numbers (N) and percentages. Statistical analyses were performed using χ 2 or Fisher’s exact test. Results were considered statistically significant with p < 0.05. Statistical analyses were conducted using SPSS software (version 20).
Results
Between March 2019 and June 2019, 100 answers were collected. Only 74 centres (48%) had a geriatrics department and a mere 21 (14%) medical oncology departments had a person dedicated to GO. The vast majority (n = 100; 88%) had the perception that the number of elderly patients with cancer seen in clinical practice had increased. Eighteen (12%) oncologists had specific protocols and geriatric scales were used at 55 (31%) centres. Almost all (91%) claimed not to apply special management practices using specific tools for every geriatric patient. There was agreement that GO afforded certain potential advantages. Finally, 99% of the oncologists surveyed believed it and that training in GO had to be improved.
Conclusions
From the nationwide survey, we conclude that there is currently no defined care structure for elderly cancer patients. There is an increasing perception of the need for training in GO. This survey reflects a reality in which specific needs are perceived.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session